TY - JOUR
T1 - Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2
T2 - Deregulation in schizophrenia
AU - Dresner, Efrat
AU - Agam, Galila
AU - Gozes, Illana
N1 - Funding Information:
This work is in partial fulfillment of the requirements for the Ph.D. degree of Ms. Efrat Dresner, an M.D. Ph.D. student at the Sackler School of Medicine which is supported in part by a stem cell student scholarship , the Lily and Avraham Gildor Chair for the Investigation of Growth Factors , the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology , the Adams Super Center for Brain Studies at Tel Aviv University , AMN Foundation, Israel and Allon Therapeutics Inc. Vancouver, Canada (I.G.). The authors are grateful to Drs. Brian Dean and Elizabeth Scarr from The Rebecca L. Cooper Research Laboratories at the Mental Health Research Institute of Victoria, Australia for kindly providing the postmortem brain specimens.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Activity-dependent neuroprotective protein (ADNP) and the homologous protein ADNP2 provide cell protection. ADNP is essential for brain formation, proper brain development and neuronal plasticity, all reported to be impaired in the schizophrenia patient brains. Furthermore, reduction in ADNP expression affects social interactions, a major hallmark of schizophrenia. To evaluate a possible involvement of ADNP and ADNP2 in the pathophysiology of schizophrenia in humans, we measured relative brain mRNA transcripts of both proteins compared with control subjects. Quantitative real time polymerase chain reaction in postmortem hippocampal specimens from normal control subjects exhibited a significant ADNP to ADNP2 transcript level correlation (r = 0.931, p< 0.001), also apparent in a neuroglial model system. In contrast, in the hippocampus of matched schizophrenia patients, this correlation (r = 0.637, p= 0.014) was drastically decreased in a statistically significant manner (p= 0.03), mirroring disease-associated increased ADNP2 transcripts. In the prefrontal cortex of schizophrenia patients the correlation between ADNP and ADNP2 mRNA levels was apparently higher than in the hippocampus (r = 0.854, p< 0.001), but did not reach a significant difference (p= 0.25). Thus, imbalance in ADNP/ADNP2 expression in the brain may impact disease progression in schizophrenia.
AB - Activity-dependent neuroprotective protein (ADNP) and the homologous protein ADNP2 provide cell protection. ADNP is essential for brain formation, proper brain development and neuronal plasticity, all reported to be impaired in the schizophrenia patient brains. Furthermore, reduction in ADNP expression affects social interactions, a major hallmark of schizophrenia. To evaluate a possible involvement of ADNP and ADNP2 in the pathophysiology of schizophrenia in humans, we measured relative brain mRNA transcripts of both proteins compared with control subjects. Quantitative real time polymerase chain reaction in postmortem hippocampal specimens from normal control subjects exhibited a significant ADNP to ADNP2 transcript level correlation (r = 0.931, p< 0.001), also apparent in a neuroglial model system. In contrast, in the hippocampus of matched schizophrenia patients, this correlation (r = 0.637, p= 0.014) was drastically decreased in a statistically significant manner (p= 0.03), mirroring disease-associated increased ADNP2 transcripts. In the prefrontal cortex of schizophrenia patients the correlation between ADNP and ADNP2 mRNA levels was apparently higher than in the hippocampus (r = 0.854, p< 0.001), but did not reach a significant difference (p= 0.25). Thus, imbalance in ADNP/ADNP2 expression in the brain may impact disease progression in schizophrenia.
KW - Activity-dependent neuroprotective protein
KW - Correlation
KW - Gene expression
KW - Hippocampus
KW - Quantitative real time polymerase chain reaction
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=79953746464&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2010.06.004
DO - 10.1016/j.euroneuro.2010.06.004
M3 - Article
C2 - 20598862
AN - SCOPUS:79953746464
SN - 0924-977X
VL - 21
SP - 355
EP - 361
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 5
ER -